Lord, Abbett & Co
IONS icon

Lord, Abbett & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Lord, Abbett & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-43,428
Closed -$1.76M – 898
2016
Q1 		$1.76M Buy
+43,428
New +$1.76M 0.01% 840
2015
Q1 		– Sell
-90,238
Closed -$5.57M – 925
2014
Q4 		$5.57M Sell
90,238
-80,221
-47% -$3.96M 0.01% 707
2014
Q3 		$6.62M Sell
170,459
-227,226
-57% -$8.05M 0.02% 685
2014
Q2 		$13.7M Buy
397,685
+312,587
+367% +$9.84M 0.03% 579
2014
Q1 		$3.68M Sell
85,098
-1,276,132
-94% -$61.9M 0.01% 836
2013
Q4 		$54.2M Sell
1,361,230
-418,379
-24% -$14.9M 0.12% 241
2013
Q3 		$66.8M Sell
1,779,609
-328,657
-16% -$9.82M 0.15% 176
2013
Q2 		$56.6M Buy
+2,108,266
New +$44.8M 0.13% 209

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Lord, Abbett & Co's IONS Position: Q2 2016 in Review

Lord, Abbett & Co sold out of Ionis Pharmaceuticals (IONS) in Q2 2016, closing a stake of 43,428 shares — an estimated $1.76M sold.

Lord, Abbett & Co first reported a position in IONS in Q2 2013 and held it in 8 quarters. The position peaked at $66.8M in Q3 2013. 282 funds tracked by Wall St. Rank hold IONS as of Q2 2016.

  • Lord, Abbett & Co reported no remaining Ionis Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Lord, Abbett & Co sold 43,428 Ionis Pharmaceuticals shares in Q2 2016, an estimated $1.76M.
  • Lord, Abbett & Co first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Lord, Abbett & Co's Ionis Pharmaceuticals position peaked at $66.8M in Q3 2013.
  • 282 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2016.

Based on Lord, Abbett & Co's 13F filing for Q2 2016, filed 12 Aug 2016.